Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku, Fuji Pharma Launch Lunabell Tablets ULD
September 27, 2013
- Maruho to Turn Maeda Pharmaceutical into Subsidiary, Expand Production Capability
September 26, 2013
- 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
- Merck, NCC Tie Up in Cancer Drug R&D for Asian Patients
September 26, 2013
- Cancer Pain Reliever E-fen Buccal Tablets Launched: Taiho, Teikoku Seiyaku
September 26, 2013
- Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
- Pfizer Japan’s Termination of CMR Agreement a Setback for Quintiles
September 25, 2013
- 1st ADC Kadcyla Approved for HER2-Positive Breast Cancer: Chugai
September 25, 2013
- Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
- Sanwa Kagaku, DSP to Terminate Copromotion Deal for Seibule
September 24, 2013
- Sanofi K.K. Launches GLP-1 Receptor Agonist Lyxumia
September 20, 2013
- Eisai’s US Unit to Collaborate with Polish Research Firm Selvita on Anticancer Agents
September 20, 2013
- MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
- Ethical Drug Sales Up 5.7% in July: Crecon Report
September 20, 2013
- Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
- Eslicarbazepine Monotherapy Meets Primary Endpoint in PIII Trials: DSP
September 19, 2013
- GSK to Return All Rights to EPO Biosimilar to JCR Pharmaceuticals
September 19, 2013
- Kyowa Kirin Aims for 10% Share in a Highly Competitive Market for Diabetes Treatments, but Onglyza’s Chances of Success Remain in Doubt
September 19, 2013
- Demand Growing for Transdermal Patches in Graying Japan, Drug Makers Gear Up for Development
September 18, 2013
- Otsuka’s Samsca Wins Add’l Indication for Fluid Retention in Liver Cirrhosis Patients; World’s 1st Such Approval
September 18, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…